Dupont Capital Management Corp Bei Gene, Ltd. Transaction History

Dupont Capital Management Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 30, 2021	SELL	$292.75 - $367.01 $422,145 - $529,228	-1,442 Closed	0 $0
Q1 2021 Apr 29, 2021	BUY	$260.64 - $382.12 $13,813 - $20,252	53 Added 3.82%	1,442 $502,000
Q4 2020 Jan 28, 2021	SELL	$221.31 - $316.61 $605,061 - $865,611	-2,734 Reduced 66.31%	1,389 $359,000
Q3 2020 Oct 29, 2020	SELL	$189.18 - $286.44 $164,397 - $248,916	-869 Reduced 17.41%	4,123 $1.18 Million
Q2 2020 Jul 24, 2020	BUY	$123.9 - $195.41 $90,942 - $143,430	734 Added 17.24%	4,992 $940,000
Q1 2020 Apr 29, 2020	BUY	$121.84 - $173.19 $71,154 - $101,142	584 Added 15.9%	4,258 $524,000
Q3 2019 Oct 28, 2019	BUY	$120.61 - $148.29 $173,075 - $212,796	1,435 Added 64.09%	3,674 $450,000
Q2 2019 Jul 30, 2019	SELL	$113.99 - $146.86 $103,046 - $132,761	-904 Reduced 28.76%	2,239 $278,000
Q1 2019 Apr 30, 2019	BUY	$122.82 - $151.83 $386,023 - $477,201	3,143 New	3,143 $415,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.